Kenvue Inc. (NYSE:KVUE) Stake Cut by TRUE Private Wealth Advisors

TRUE Private Wealth Advisors lessened its holdings in Kenvue Inc. (NYSE:KVUE) by 8.4% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 10,870 shares of the company’s stock after selling 995 shares during the quarter. TRUE Private Wealth Advisors’ holdings in Kenvue were worth $251,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also modified their holdings of KVUE. FMR LLC grew its stake in Kenvue by 2.3% during the 3rd quarter. FMR LLC now owns 137,915,493 shares of the company’s stock worth $3,189,985,000 after buying an additional 3,075,019 shares during the last quarter. Massachusetts Financial Services Co. MA grew its position in shares of Kenvue by 8.9% during the third quarter. Massachusetts Financial Services Co. MA now owns 86,979,341 shares of the company’s stock worth $2,011,832,000 after acquiring an additional 7,115,374 shares during the last quarter. Bank of New York Mellon Corp increased its holdings in shares of Kenvue by 21.0% in the 2nd quarter. Bank of New York Mellon Corp now owns 43,444,085 shares of the company’s stock worth $789,813,000 after acquiring an additional 7,546,362 shares during the period. American Century Companies Inc. lifted its position in Kenvue by 20.7% in the 2nd quarter. American Century Companies Inc. now owns 27,382,644 shares of the company’s stock valued at $497,816,000 after purchasing an additional 4,700,697 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its stake in Kenvue by 2.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 24,411,207 shares of the company’s stock valued at $564,689,000 after purchasing an additional 547,874 shares during the period. 97.64% of the stock is owned by institutional investors and hedge funds.

Kenvue Price Performance

NYSE KVUE opened at $24.08 on Friday. Kenvue Inc. has a 1 year low of $17.67 and a 1 year high of $24.46. The stock’s 50-day moving average price is $22.94 and its two-hundred day moving average price is $20.99. The company has a market cap of $46.17 billion, a PE ratio of 43.78, a PEG ratio of 2.19 and a beta of 1.36. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66.

Kenvue (NYSE:KVUE) last posted its quarterly earnings data on Thursday, November 7th. The company reported $0.28 earnings per share for the quarter, topping the consensus estimate of $0.27 by $0.01. The firm had revenue of $3.90 billion for the quarter, compared to analysts’ expectations of $3.92 billion. Kenvue had a net margin of 6.88% and a return on equity of 21.43%. The company’s quarterly revenue was down .4% compared to the same quarter last year. During the same period in the previous year, the company posted $0.31 EPS. On average, analysts predict that Kenvue Inc. will post 1.07 EPS for the current year.

Kenvue Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Wednesday, November 27th. Shareholders of record on Wednesday, November 13th were paid a dividend of $0.205 per share. The ex-dividend date was Wednesday, November 13th. This represents a $0.82 annualized dividend and a yield of 3.41%. Kenvue’s dividend payout ratio (DPR) is presently 149.09%.

Wall Street Analysts Forecast Growth

KVUE has been the topic of several analyst reports. Royal Bank of Canada lowered shares of Kenvue from an “outperform” rating to a “sector perform” rating and set a $24.00 price target on the stock. in a research note on Tuesday, September 24th. Bank of America raised their price target on Kenvue from $24.00 to $27.00 and gave the company a “buy” rating in a report on Tuesday, October 22nd. Jefferies Financial Group initiated coverage on shares of Kenvue in a report on Tuesday, September 24th. They issued a “buy” rating and a $27.00 price objective for the company. Piper Sandler upped their price target on shares of Kenvue from $20.00 to $21.00 and gave the stock a “neutral” rating in a research note on Monday, September 23rd. Finally, Deutsche Bank Aktiengesellschaft increased their price target on Kenvue from $23.00 to $24.00 and gave the company a “buy” rating in a research note on Wednesday, August 7th. One research analyst has rated the stock with a sell rating, seven have given a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat, Kenvue presently has an average rating of “Hold” and a consensus price target of $22.64.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.